Nucleic acid that inhibits expression of irf5
US-2017081667-A1 · Mar 23, 2017 · US
Method of treating severe asthma
US10420792B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10420792-B2 |
| Application number | US-201815903505-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 23, 2018 |
| Priority date | Feb 24, 2017 |
| Publication date | Sep 24, 2019 |
| Grant date | Sep 24, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Methods are provided for treating corticosteroid-resistant asthma in a patient, comprising decreasing Interferon Regulatory Factor 5 (IRF5) activity in the patient. Antisense or RNA interference reagents and methods can be used to decrease IRF5 activity in the patient.
First claim
Opening claim text (preview).
We claim: 1. A method of treating corticosteroid-insensitive asthma in a patient displaying a Th1 immune profile, comprising reducing IRF5 activity to a level effective to treat one or more symptoms of asthma in a patient. 2. The method of claim 1 , wherein the patient displays a Th1/Th17hiTh2lo immune profile. 3. The method of claim 1 , further comprising administering an effective amount of corticosteroid to the patient. 4. The method of claim 3 , wherein the corticosteroid is administered locally in the respiratory tract. 5. The method of claim 1 , wherein IRF5 expression is reduced by administering to the patient a nucleic acid or an analog thereof able to decrease IRF5 expression in the patient. 6. The method of claim 5 , wherein the nucleic acid or analog thereof is an antisense reagent. 7. The method of claim 5 , wherein the nucleic acid or analog thereof is an interfering nucleic acid or analog thereof acting by RNA interference (RNAi). 8. The method of claim 7 , wherein the interfering nucleic acid or analog thereof is an interfering microRNA (miRNA) reagent or an interfering small interfering RNA (siRNA) reagent. 9. The method of claim 5 , wherein the nucleic acid or analog thereof is a ribozyme reagent. 10. The method of claim 1 , wherein IRF5 activity is decreased using a binding reagent specific to IRF5. 11. The method of claim 10 , wherein the binding reagent is an anti-IRF5 antibody, or antibody fragment, such as a recombinant scFv fragment.
Assignees
Inventors
Classifications
Antiasthmatics · CPC title
- A61K31/713Primary
Double-stranded nucleic acids or oligonucleotides · CPC title
Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00 · CPC title
substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10420792B2 cover?
- Methods are provided for treating corticosteroid-resistant asthma in a patient, comprising decreasing Interferon Regulatory Factor 5 (IRF5) activity in the patient. Antisense or RNA interference reagents and methods can be used to decrease IRF5 activity in the patient.
- Who is the assignee on this patent?
- Univ Of Pittsburgh—Of The Commonwealth System Of Higher Education, The Univ Of Pittsburgh—Of The Commonwealth System Of Higher Education
- What technology area does this patent fall under?
- Primary CPC classification A61K31/713. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Sep 24 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 3 related publications on this page (citations in our corpus or others sharing the same primary CPC).